Checkpoint Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Checkpoint Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Checkpoint Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Checkpoint Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Checkpoint Therapeutics Inc (Checkpoint), a subsidiary of Sun Pharmaceutical Industries Ltd, is a biotechnology company. It focuses on immunotherapy and targeted oncology for solid tumor cancers. Checkpoint's major product is UNLOXCYT, a PD-L1 blocking antibody approved for treating metastatic and locally advanced cutaneous squamous cell carcinoma. The company’s product candidate, cosibelimab, an anti-PD-L1 antibody, is undergoing a Phase 1 clinical trial for patients with cutaneous squamous cell carcinoma (CSCC). Checkpoint is developing olafertinib, a third-generation EGFR inhibitor for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The company is also advancing CK-302, an anti-GITR monoclonal antibody, CK-103, a small-molecule BET inhibitor, and an anti-CAIX antibody targeting renal cell carcinoma, all designed to enhance anti-tumor responses. The company's products are primarily used by healthcare providers to treat patients with specific types of cancer. The company operates in multiple geographic locations, targeting markets in the United States and potentially Europe and other regions. Checkpoint is headquartered in Waltham, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 110, 95 Sawyer Road, Waltham, Massachusetts, 02453
Website
checkpointtx.com
Telephone
1 781 6524500
No of Employees
24
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$41,000
Checkpoint Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| UNLOXCYT |
| Pipeline: |
| Cosibelimab |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In May, the company was acquired by Sun Pharmaceutical Industries Limited. |
| 2025 | Contracts/Agreements | In March, the company signed an agreement to be acquired by Sun Pharmaceutical Industries Limited. |
| 2024 | Contracts/Agreements | In July, the company collaborated with GC Cell’s Immuncell-LC to explore the combined therapeutic potential of cosibelimab. |
Competitor Comparison
| Key Parameters | Checkpoint Therapeutics Inc | Merck & Co Inc | AstraZeneca Plc | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United Kingdom | United States of America | Switzerland |
| City | Waltham | Rahway | Cambridge | North Chicago | Basel |
| State/Province | Massachusetts | New Jersey | Cambridgeshire | Illinois | Basel-Stadt |
| No. of Employees | 24 | 73,000 | 94,300 | 55,000 | 75,883 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Weiss | Chairman | Executive Board | 2015 | 60 |
| James F. Oliviero, III | Chief Executive Officer; Director; President | Executive Board | 2018 | 50 |
| Garrett Gray | Secretary; Treasurer; Chief Financial Officer | Senior Management | 2020 | 38 |
| Christian Bechon | Director | Non Executive Board | 2018 | 66 |
| Lindsay A. Rosenwald, M.D. | Director | Non Executive Board | 2014 | 69 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer